Everett Harris Co Ca Lowers stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Everett Harris Co Ca reduced its stake in AbbVie Inc by 1.47% during the most recent quarter end. The investment management company now holds a total of 449,261 shares of AbbVie Inc which is valued at $29,907,305 after selling 6,724 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 3, 2016.AbbVie Inc makes up approximately 1.04% of Everett Harris Co Ca’s portfolio.

Other Hedge Funds, Including , Mutual Of America Capital Management boosted its stake in ABBV in the latest quarter, The investment management firm added 23,522 additional shares and now holds a total of 204,628 shares of AbbVie Inc which is valued at $13,622,086. AbbVie Inc makes up approx 0.28% of Mutual Of America Capital Management’s portfolio.Atlas Browninc. boosted its stake in ABBV in the latest quarter, The investment management firm added 1,251 additional shares and now holds a total of 24,422 shares of AbbVie Inc which is valued at $1,617,469. AbbVie Inc makes up approx 0.65% of Atlas Browninc.’s portfolio.Investors Asset Management Of Georgia Inc Ga Adv boosted its stake in ABBV in the latest quarter, The investment management firm added 800 additional shares and now holds a total of 9,810 shares of AbbVie Inc which is valued at $625,976. AbbVie Inc makes up approx 0.47% of Investors Asset Management Of Georgia Inc Ga Adv’s portfolio.

AbbVie Inc closed down -0.2 points or -0.30% at $66.34 with 53,09,293 shares getting traded on Monday. Post opening the session at $66.38, the shares hit an intraday low of $65.75 and an intraday high of $66.67 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.